Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper

Bioanalysis

Volumn 5, Issue 9, 2013, Pages 997-1006

  Gorovits, Boris ^a   Alley, Stephen C ^b   Bilic, Sanela ^c   Booth, Brian ^d   Kaur, Surinder ^e   Oldfield, Phillip ^f   Purushothama, Shobha ^g   Rao, Chetana ^h   Shord, Stacy ^d   Siguenza, Patricia ^e  

^a PFIZER INC   (United States)

^b SEATTLE GENETICS INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e GENENTECH INC   (United States)

^f Biogen Idec Inc ^*  (Canada)

^g BIOGEN   (United States)

^h Bristol Myers Squibb Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADECETRIS; ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CALICHEAMICIN LYSINE CONJUGATE; CANTUZUMAB MERTANSINE; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VEDOTIN CD30 MONOCLONAL ANTIBODY CONJUGATE;

ACCURACY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNOASSAY; IN VIVO STUDY; MEDICAL SOCIETY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; HUMANS; IMMUNOCONJUGATES; PHARMACEUTICAL PREPARATIONS; RESEARCH REPORT; UNITED STATES;

EID: 84877245142     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.38     Document Type: Article

References (36)

1. Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17(20), 6389-6397 (2011).
2. Glennie MJ, Van DE, Winkel JGJ. Renaissance of cancer therapeutic antibodies. Drug Discov. Today 8(11), 503-510 (2003).
3. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157(2), 220-233 (2009).
4. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23(9), 1137-1146 (2005).
5. Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7(6), 1490-1496 (2001). Erratum appears in Clin. Cancer Res. 2002 8(1), 300 (2002).
6. De Claro RA, Mcginn K, Kwitkowski V et al. US Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin. Cancer Res. 18(21), 5845-5849 (2012).
7. US FDA. News Release. FDA approves new treatment for late-stage breast cancer. 22 February 2013.
8. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm. Res. 29(9), 2354-2366 (2012).
9. Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M. Bioanalytical assay strategies for the development of antibody drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226 (2013).
10. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review. Application Number: 125388Orig1s000. US FDA, Washington, DC, USA (2011).
11. US FDA. Draft Guideline. Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. US FDA, Washington, DC, USA (2009).
12. Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. European Medicines Agency, London, UK (2007).
13. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008).
14. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004).
15. Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1-2), 1-9 (2008).
16. Stephan JP, Chan P, Lee C et al. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug. Chem. 19(8), 1673-1683 (2008).
17. Hamblett KJ, Senter PD, Chace DF et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10(20), 7063-7070 (2004).
18. Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 14(9), 2436-2446 (2005).
19. Lewis Phillips GD, Li G, Dugger Dl et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68(22), 9280-9290 (2008).
20. Dijoseph JF, Armellino DC, Boghaert ER et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5), 1807-1814 (2004).
21. Junutula JR, Raab H, Clark S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26(8), 925-932 (2008).
22. Shen B-Q, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30(2), 184-189 (2012).
23. Alley SC, Zhang X, Okeley Nm et al. The pharmacologic basis for antibody-auristatin conjugate activity. J. Pharmacol. Exp. Ther. 330(3), 932-938 (2009).
24. Baldwin AD, Kiick KL. Tunable degradation of maleimide-thiol adducts in reducing environments. Bioconjug. Chem. 22(10), 1946-1953 (2011).
25. Alley SC, Benjamin DR, Jeffrey SC et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 19(3), 759-765 (2008).
26. Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. (2012).
27. Xu K, Liu L, Saad OM et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal. Biochem. 412(1), 56-66 (2011).
28. Xie H, Audette C, Hoffee M et al. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J. Pharmacol. Exp. Ther. 308(3), 1073-1082 (2004). Erratum appears in J. Pharmacol. Exp. Ther. 2004 310(2), 844 (2004).
29. Sanderson RJ, Hering MA, James SF et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11(2 Pt 1), 843-852 (2005).
30. Stephan JP, Kozak KR, Wong WLT. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 3(6), 677-700 (2011).
31. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003).
32. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007).
33. Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloidleukemia. J. Clin. Pharmacol. 44(8), 873-880 (2004).
34. Baillie TA, Cayen MN, Fouda H et al. Drug metabolites in safety testing. Toxicol Appl Pharmacol 182(3), 188-196 (2002).
35. US FDA. Guidance for Industry: Safety Testing of Drug Metabolites. US FDA, Washington, DC, USA (2008).
36. US FDA. Guidance for Industry: Bioanalytical Method Validation. US FDA, Washington, DC, USA (2001).